The minds behind ArcticZymes Technologies

We, at ArcticZymes Technologies, are aware of the critical role enzymes play in research, diagnostics and therapeutics. This understanding drives our team of highly dedicated scientists and experienced managers to work with passion and dedication at the highest level to exceed the expectations of our partners.

The management team


Dr Jethro Holter, CEO

Dr Jethro Holter (born 1972) joined ArcticZymes as Managing Director on January 1st, 2015 and was appointed interim CEO on October 23rd 2019 and then became permanent CEO on 22nd April, 2020. He has previous experience from Life Technologies (Thermo Fisher Scientific) in international business development of B2B/OEM solutions with Diagnostic and Life Science companies as well as other commercial experience. Earlier in his career, he was R&D Director at Mole Genetics AS developing automated sample prep solutions. Jethro Holter holds a Ph.D in Molecular Neuroscience from Cardiff University, UK. Number of shares in Biotec Pharmacon held by Dr Holter: 564. Number of options in Biotec Pharmacon held by Dr Holter: 0

Børge Sørvoll, CFO

Børge Sørvoll (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a Master’s Degree in Business and Administration from the University of Wyoming. Number of shares in Biotec Pharmacon held by Mr. Sørvoll: 25,428


The board of directors


Dr Marie Ann Roskrow, Chairperson

Dr Roskrow gained a BSc (Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Number of shares in Biotec Pharmacon held by Dr Roskrow: 0

Volker Wedershoven, Director

Mr. Wedershoven has a MBA from Ludwig-Maximilians-University, Munich, Germany and has a wide background within entrepreneurship, finance and strategy. Mr. Wedershoven has more than 30 years of industrial experience and was amongst others responsible for development of Seidenader Machinenbau, a global supplier of production equipment to the pharmaceutical industry. He sold the company in 2010 with close to 500 employees to a large equipment supplier in Germany. Mr. Wedershoven holds several board and management positions in smaller German companies. Number of shares in Biotec Pharmacon held by Mr. Wedershoven: 80,000


Dr Marit Sjo Lorentzen, Director – employee representative

Dr Lorentzen has a Civil engineering degree in Biotechnology and a Dr. Scient in Molecular Biology degree from the University of Tromsø. Marit worked at the University of Tromsø until 2011. She has extensive work experience within laboratory operations, management and research. This also includes experience within teaching, field of studies in biochemistry, molecular biology, microbiology, fermentation and purification. She holds a position as Director of Operations in ArcticZymes Technologies. Number of shares in Biotec Pharmacon held by Dr Lorentzen: 20,331